I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
May 27 / Springer Healthcare

ATS 2021 in-depth report: Chronic Obstructive Pulmonary Disease

Description

This ATS 2021 in-depth report provides an overview of new insights in pulmonary rehabilitation.

American Thoracic Society

ATS 2021 Annual Meeting

May 14th – 19th, 2021

In-Depth Report: Chronic Obstructive Pulmonary Disease

The 2021 Annual Congress of the American Thoracic Society (ATS) was held between May 14th and 19th and showcased the latest advances and breakthrough discoveries that will reshape the future of respiratory science, patient care and global respiratory health. A robust scientific, educational and networking programme was delivered via the virtual ATS platform, which included clinical and scientific sessions, keynote series, postgraduate courses and meet the expert sessions.

ATS President Juan Celedón

Juan Celedón, ATS President

ATS 2021 got underway with the opening ceremony and an address by current President Juan Celedón, who highlighted the extreme challenges of the past year which ATS has addressed with advocacy and a renewed focus on its over-arching mission to advance research and careers, clinical care and public health. Incoming President-Elect Lynn Schnapp then outlined key priorities and opportunities for the year ahead which include infrastructure upgrades, the leveraging of new learning methods and technologies and an increased focus on collaboration and knowledge-sharing.

 
“This past year, a once-in-a-century catastrophe has revealed the character and commitment of our ATS members who confronted the COVID-19 pandemic with selfless devotion to prevent further suffering and help those afflicted.”

ATS President, Juan Celedón

 

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

New Insights in Pulmonary Rehabilitation

Anja Frei, Zurich, Switzerland, showcased results from a randomised controlled trial assessing the effectiveness of a 1-year home-based maintenance exercise training programme (HOMEX) versus usual care in 123 patients with chronic obstructive pulmonary disease (COPD) after pulmonary rehabilitation (PR). Although there was no significant difference in the primary outcome of change in conventional interviewer led dyspnoea, HOMEX training did provide benefit in functional exercise capacity assessed by the 1-minute-sit-to-stand test.

Two fifths of Medicare beneficiaries with COPD in the US have poor access to PR according to research presented by Gargya Malla, Birmingham, USA, with the deficit more prominent in rural areas and the south. It is therefore important to consider other cost-effective methods of tele-, home- and web-based PR, Dr Malla concluded.

Research by Enya Daynes, Leicester, UK, explored the need for PR following a COVID-19 hospitalisation in 938 patients admitted to University Hospitals of Leicester (UHL). Up to 30% of patients self-identified rehabilitation needs, as did 61% of those contacted. This equates to a large volume of patients requiring intervention and may place an increased burden on existing PR programmes as lockdowns ease, Dr Daynes cautioned.

Abebaw Yohannes, Azusa, USA, analysed predictors of premature discontinuation in 993 patients with COPD participating in an 8-week PR programme. Over a quarter of patients discontinued the PR course early, with younger age, elevated symptoms of dyspnoea and anxiety, and reduced exercise tolerance being significant predictive factors.

Proportion of patients with COPD who experienced premature discontinuation in an 8-week PR programme

Lower limb muscle ultrasound using two muscles can be used to predict low appendicular lean mass according to findings from a cross-sectional study of 61 adult lung transplant candidates. Manoela de Paula Ferreira, Montreal, Canada, suggested that this method may offer a simple, low-cost approach to evaluate muscle size and screen for the presence of sarcopenia. Secondary analysis of data from two RCTs involving 209 patients with COPD showed that baseline functional status was strongly associated with response to a web-based physical activity intervention. Discordance between what patients can do and what they actually do may be related to age, dyspnoea, forced expiratory volume in one second (FEV1%) predicted and exercise confidence, concluded Stephanie Robison, Boston, USA.

 

Abebaw Yohannes, Azusa, USA, carried out a network analysis of symptoms of depression and anxiety among 1587 patients with COPD in the COPDGene study. Activity limitation, psychomotor slowing and sleep problems were pinpointed as the most relevant ‘bridging symptoms’ between COPD and depression/anxiety.

 

“Network analyses identified meaningful clinical symptom connections that highlight the complex interaction between physical and psychological features in COPD patients.

Abebaw Yohannes, Azusa, USA

 
Closing Remarks

Looking ahead to next year’s congress, ATS is planning a live, in-person event in San Francisco which will be complemented by a rich array of online content. This hybrid conference will take place in May 2022, with final dates to be confirmed.

 

©Springer Healthcare 2021. This content has been independently selected and developed by Springer Healthcare and licensed by Roche for Medically. The topics covered are based on therapeutic areas specified by Roche. This content is not intended for use by healthcare professionals in the UK, US or Australia. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.